Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity
Author:
Affiliation:
1. Laboratory of Nano- and Translational Medicine
2. Department of Radiation Oncology
3. Lineberger Comprehensive Cancer Center
4. Carolina Center for Cancer Nanotechnology Excellence
5. University of North Carolina at Chapel Hill
Abstract
We demonstrate proof of principle that nanoparticle delivery of chemosensitizers can improve efficacy of chemotherapy without increasing toxicity.
Funder
National Institutes of Health
Publisher
Royal Society of Chemistry (RSC)
Subject
General Materials Science
Link
http://pubs.rsc.org/en/content/articlepdf/2015/NR/C4NR07102F
Reference21 articles.
1. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
2. Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
3. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
4. Delivering nanomedicine to solid tumors
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer;Nanoscale;2024
2. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer;International Journal of Nanomedicine;2023-09
3. Nanocarriers in The Treatment of Head and Neck Cancer;Therapeutic Nanocarriers in Cancer Treatment: Challenges and Future Perspective;2023-03-05
4. Advances in Lipid‐Based Codelivery Systems for Cancer and Inflammatory Diseases;Advanced Healthcare Materials;2022-12-16
5. PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma;iScience;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3